Drug intelligence / Profile preview

ampicillin-sulbactam + betamethasone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Oral, Topical

Overview

A combination of ampicillin-sulbactam (an antibiotic) and betamethasone (a corticosteroid). Ampicillin-sulbactam combines a penicillin antibiotic with a beta-lactamase inhibitor to treat bacterial infections by preventing bacterial cell wall synthesis and protecting ampicillin from enzymatic breakdown. Betamethasone is a corticosteroid that reduces inflammation by activating natural substances in the body to decrease swelling, redness, and itching.

Targets

Class A BL (Class A beta-lactamase)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)GR (Glucocorticoid receptor)PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on ampicillin-sulbactam + betamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin-sulbactam + betamethasone.

Explore the full profile